OncLive TV

Dr Hilton on the Impact of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 19th 2023

Christie J. Hilton, DO, discusses the impact of trastuzumab deruxtecan on the treatment of patients with HER2-positive metastatic breast cancer and ongoing research with the agent in this patient population.

Dr Dhanji on Hypertension as a Risk Factor for Mortality in Urothelial Cancer

May 19th 2023

Sohail Dhanji, MD, discusses the investigation of preoperative hypertension as a risk factor in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, as well as other risk factors for mortality in this patient population.

Dr Stone on the Association of Language Barriers and PSA Screening for Prostate Cancer

May 19th 2023

Benjamin V. Stone, MD, discusses the association between language barriers and prostate-specific antigen screening rates in American men.

Dr Rini on the OPTIC RCC Trial in Advanced Kidney Cancer

May 19th 2023

Brian I. Rini, MD, FASCO, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial.

Dr Hays on the Evolution of Later-line Treatment Options in Refractory mCRC

May 19th 2023

John L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.

Dr Phillips on the FDA Approval of Epcoritamab in R/R DLBCL

May 19th 2023

Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr Mascarenhas on Ongoing Research in Myelofibrosis

May 18th 2023

John Mascarenhas, MD, discusses ongoing trials and research in myelofibrosis.

Dr Gupta on the Background of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

May 18th 2023

Shilpa Gupta, MD, discusses the background of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Dr Singer on the Safety of Perioperative Nivolumab and Cabozantinib in RCC

May 18th 2023

Eric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.

Dr Grieb on MYC in CRC

May 18th 2023

Brian C. Grieb, MD, PhD, discusses historical barriers to targeting the MYC oncogene in patients with colorectal cancer and the rationale for an ongoing phase 1/2 clinical trial that may demonstrate an effective way to target MYC in CRC and other solid tumors. 

Dr Bal on Ide-cel in R/R Multiple Myeloma

May 18th 2023

Susan Bal, MD, assistant professor, University of Alabama at Birmingham, discusses key efficacy and safety data from the phase 2 KarMMa trial in patients with relapsed/refractory multiple myeloma.

Dr Cole on the Rationale for Investigating Race-based Disparities in Prostate Cancer–Specific Survival

May 18th 2023

Alexander Putnam Cole, MD, discusses the rationale for investigating the magnitude of racial and ethnic disparities in prostate cancer–specific survival in patients undergoing surgery vs radiotherapy.

Dr Das on the Use of Neoadjuvant and Adjuvant Chemoimmunotherapy Regimens in NSCLC

May 18th 2023

Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.

Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis

May 17th 2023

Morie A. Gertz, MD, discusses the rationale for the phase 3 AFFIRM-AL trial in patients with amyloid light chain amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.

Dr Suvannasankha on the Potential Mitigation of CRS With REGN5459 in R/R Myeloma

May 17th 2023

Attaya Suvannasankha, MD, discusses addressing the incidence of cytokine release syndrome in a first-in-human phase 1/2 trial for patients with relaped/refractory multiple myeloma.

Dr Muslimani on Unanswered Questions to be Addressed in HER2+ mCRC

May 17th 2023

Alaa Muslimani, MD, discusses unanswered questions in the treatment of patients with metastatic colorectal cancer, highlighting how these unmet needs may be addressed through continued research.

Dr Mina on the Evolution of T-DM1 and T-DXd in HER2+ Breast Cancer

May 17th 2023

Lida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer.

Diagnostic Challenges and Clinical Updates in Soft Tissue Sarcomas

May 17th 2023

Advances in the Diagnosis and Treatment of BPDCN

May 17th 2023

Dr Stokes on Radiation Vs Surgery in HPV+ OPSCC

May 16th 2023

William (Bill) Stokes, MD, discusses the use of radiation vs surgery for the treatment of patients with human papillomavirus–related oropharyngeal squamous cell carcinoma.